STOCK TITAN

iBio: IBIO-610 primate study shows 9.6% lower fat

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

iBio, Inc. (IBIO) reported extended preclinical results for its long-acting Activin E-targeting antibody IBIO-610 in obese non-human primates, with observations through 28 weeks. The study included 5 animals receiving IBIO-610 and 6 receiving vehicle. At week 28, the IBIO-610 group showed a 2.3% reduction in body weight relative to vehicle. At week 24, total fat was 9.6% lower, abdominal subcutaneous fat 16.6% lower and visceral fat 10.96% lower relative to vehicle; lean mass was generally maintained. Active Activin E was nearly completely suppressed through week 28.

In separate preclinical work, an antibody-peptide fusion selectively bound and activated amylin receptors 1 and 3, with minimal binding to or activation of the calcitonin receptor alone. A single-dose study in lean rats found reduced food intake over 24 hours versus vehicle. The amylin data are to be presented at PEGS Europe 2026 and the Amylin-Based Therapeutics Summit; iBio plans further preclinical studies in diet-induced obesity models.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
IBIO-610 study group 5 animals Obese non-human primates receiving IBIO-610
Vehicle group 6 animals Obese non-human primate study
Body-weight reduction 2.3% IBIO-610 group relative to vehicle at week 28
Total fat difference 9.6% lower IBIO-610 group relative to vehicle at week 24
Abdominal subcutaneous fat difference 16.6% lower IBIO-610 group relative to vehicle at week 24
Visceral fat difference 10.96% lower IBIO-610 group relative to vehicle at week 24
Activin E-targeting antibody medical
"long-acting Activin E-targeting antibody, IBIO-610"
non-human primate (NHP) medical
"non-human primate (NHP) study"
Non-human primate (NHP) refers to monkeys, apes or other primate species used in medical research to test safety and effectiveness before treatments are given to people. Because their biology is closer to humans than other lab animals, results from NHP studies can strongly influence whether regulators allow human trials, how quickly a drug advances, and the cost, timing and risk profile investors use to value biotech projects — like a dress rehearsal that helps predict real-world performance.
amylin receptor agonist medical
"selective amylin receptor agonist"
An amylin receptor agonist is a drug that activates the body’s amylin receptors to mimic the hormone amylin, which helps slow stomach emptying, reduce appetite, and regulate blood sugar. For investors, these medicines matter because clinical trial results, safety profiles, and regulatory approval determine their commercial potential in diabetes and obesity markets—similar to how a new feature can change a product’s appeal and sales prospects.
antibody-peptide fusion technical
"the Company’s antibody-peptide fusion"
calcitonin receptor medical
"minimal binding to or activation of the calcitonin receptor alone"
A cell-surface receptor protein that binds the hormone calcitonin and, when activated, triggers intracellular signaling pathways that influence calcium handling and bone resorption. The calcitonin receptor is a G‑protein–coupled receptor whose functional properties and which peptides it responds to can change when it pairs with receptor activity–modifying proteins (RAMPs); those pairings alter ligand specificity and tissue distribution, so effects depend on the receptor’s molecular partners and where it is expressed in the body.
in vitro medical
"In vitro, the Company’s antibody-peptide fusion"
In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IBIO-610 show in iBio's primate study?

In obese non-human primates, the IBIO-610 group showed a 2.3% reduction in body weight relative to vehicle at week 28; at week 24, total fat was 9.6% lower, abdominal subcutaneous fat 16.6% lower and visceral fat 10.96% lower. The study included 5 treated animals and 6 receiving vehicle.

What did iBio's amylin program show?

In vitro, the antibody-peptide fusion selectively bound and activated amylin receptors 1 and 3, with minimal binding to or activation of the calcitonin receptor alone. A single-dose study in lean rats found reduced food intake over 24 hours compared with vehicle.

When will iBio present its amylin data?

The PEGS Europe 2026 oral presentation is scheduled for November 19, 2026, at 11:15 a.m. WET. The Amylin-Based Therapeutics Summit presentation is scheduled for December 2, 2026, at 1:30 p.m. ET.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001420720false00014207202026-11-162026-11-16

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 16, 2026

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

​

​

001-35023

26-2797813

(Commission File Number)

(IRS Employer Identification No.)

​

11750 Sorrento Valley Road, Suite 200

San Diego, California 92121

(Address of principal executive offices and zip code)

(979) 446-0027

(Registrant’s telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

IBIO

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 7.01. Regulation FD Disclosure.

On November 16, 2026, iBio, Inc. (the “Company”) issued a press release highlighting extended preclinical data from a non-human primate (NHP) study of IBIO-610 presented at ObesityWeek 2026, as well as preclinical data from its amylin program to be presented at PEGS Europe 2026 and the Amylin-Based Therapeutics Summit.

​

The new data for the Company’s long-acting Activin E-targeting antibody, IBIO-610, builds on previously reported findings from an obese NHP study, extending observations through 28 weeks. The study included obese NHPs receiving IBIO-610 (n=5) or vehicle (n=6). IBIO-610 was initially administered every eight weeks, followed by more frequent dosing and a dose-free period.

​

Key findings were as follows:

​

·At week 28, the IBIO-610 group showed a 2.3% reduction in body weight relative to vehicle, with change in body weight first observed around week 18. At week 24, total fat was 9.6% lower, abdominal subcutaneous fat was 16.6% lower and visceral fat was 10.96% lower relative to vehicle, while lean mass was generally maintained.

​

·Near-complete suppression of active Activin E was observed through week 28.

​

The Company’s amylin program combines a receptor-targeting antibody with a fused peptide agonist and demonstrated highly selective activation of amylin receptors 1 and 3.

​

Key findings were as follows:

​

·In vitro, the Company’s antibody-peptide fusion selectively bound and activated amylin receptors 1 and 3, with minimal binding to or activation of the calcitonin receptor alone.

​

·In a single-dose study in lean rats, the rats dosed with the Company’s selective amylin receptor agonist had reduced food intake over 24 hours compared with vehicle.

​

The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

Item 8.01. Other Events.

On November 16, 2026, the Company issued a press release highlighting extended preclinical data from a non-human primate (NHP) study of IBIO-610 presented at ObesityWeek 2026, as well as preclinical data from its amylin program to be presented at PEGS Europe 2026 and the Amylin-Based Therapeutics Summit.

​

The new data for the Company’s long-acting Activin E-targeting antibody, IBIO-610, builds on previously reported findings from an obese NHP study, extending observations through 28 weeks. The study included obese NHPs receiving IBIO-610 (n=5) or vehicle (n=6). IBIO-610 was initially administered every eight weeks, followed by more frequent dosing and a dose-free period.

​

Key findings were as follows:

​

·At week 28, the IBIO-610 group showed a 2.3% reduction in body weight relative to vehicle, with change in body weight first observed around week 18. At week 24, total fat was 9.6% lower, abdominal subcutaneous fat was 16.6% lower and visceral fat was 10.96% lower relative to vehicle, while lean mass was generally maintained.

​

·Near-complete suppression of active Activin E was observed through week 28.

​

The Company’s amylin program combines a receptor-targeting antibody with a fused peptide agonist and demonstrated highly selective activation of amylin receptors 1 and 3.

​

Key findings were as follows:

​

·In vitro, the Company’s antibody-peptide fusion selectively bound and activated amylin receptors 1 and 3, with minimal binding to or activation of the calcitonin receptor alone.

​

·In a single-dose study in lean rats, the rats dosed with the Company’s selective amylin receptor agonist had reduced food intake over 24 hours compared with vehicle.

​

Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits

​

​

​

Exhibit No.

  ​ ​ ​

Description

99.1

​

Press Release, issued by iBio, Inc. dated November 16, 2026

104

​

Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

​

​

Date: November 16, 2026

IBIO, INC.

 

 

​

By: 

/s/ Marc A. Banjak

 

 

Name:

Marc A. Banjak

​

​

Title:

Chief Legal Officer

​

Exhibit 99.1

iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences

​

ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28.

​

Amylin program data demonstrating reduced food intake in rats to be presented at PEGS Europe and the Amylin-Based Therapeutics Summit

​

Together, the findings highlight the potential of iBio’s antibody discovery platform to generate highly specific candidates against distinct targets

​

SAN DIEGO, November 16, 2026 -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced extended preclinical data from a non-human primate (NHP) study of IBIO-610, potentially a first-in-class Activin E antibody candidate, presented at ObesityWeek 2026, as well as preclinical data from its amylin program to be presented at PEGS Europe 2026 and the Amylin-Based Therapeutics Summit.

​

“These data demonstrate the power of our AI-enabled antibody discovery platform to generate potent, highly specific molecules against challenging targets,” said Martin Brenner, DVM, Ph.D., chief executive officer and chief scientific officer of iBio. “The sustained effects observed in our NHP study strengthen our belief in IBIO-610’s potential to offer a differentiated approach to long-term weight management. Durable Activin E suppression, reductions in fat mass while generally maintaining lean mass, and the newly observed reduction in body weight provide a more comprehensive perspective of how this approach may improve the quality of weight loss. Beyond IBIO-610, our amylin program has taken an important step forward, demonstrating high selectivity for amylin receptors and reduced food intake in a preclinical model. We believe this selective approach has the potential to improve the balance of efficacy and tolerability and look forward to evaluating it in further studies. By pursuing multiple distinct mechanisms, we have the opportunity to build a complementary portfolio of medicines with the potential to extend the cardiometabolic benefits of weight loss beyond current therapies.”

​

IBIO-610 Activin E Data presented at ObesityWeek 2026

The new data for iBio’s long-acting Activin E-targeting antibody, IBIO-610, builds on previously reported findings from an obese NHP study, extending observations through 28 weeks.

​

The study included obese NHPs receiving IBIO-610 (n=5) or vehicle (n=6). IBIO-610 was initially administered every eight weeks, followed by more frequent dosing and a dose-free period.

​

​


Key findings:

​

·

IBIO-610 reduced weight gain despite continued high-fat feeding, with body weight beginning to diverge from the vehicle group around Week 18 and reaching a 2.3% difference by Week 28.

​

·

At Week 24, total body fat was 9.6% lower, abdominal subcutaneous fat 16.6% lower, and visceral fat 10.96% lower compared with vehicle, while lean mass was generally maintained.

​

·

Near-complete suppression of active Activin E was observed through week 28.

​

These findings build on previously reported data from the NHP study and further support IBIO-610’s potential to promote fat-selective effects while maintaining lean mass.

​

Amylin Program Data to Be Presented at PEGS Europe and the Amylin-Based Therapeutics Summit

​

iBio’s amylin program combines a receptor-targeting antibody with a fused peptide agonist and demonstrated highly selective activation of amylin receptors 1 and 3. The findings highlight the platform’s ability to generate highly specific antibodies against challenging targets and support the development of a potential long-acting amylin therapeutic.

​

Key findings:

​

·

In vitro, iBio’s antibody-peptide fusion selectively bound and activated amylin receptors 1 and 3, with minimal binding to or activation of the calcitonin receptor alone.

​

·

In a single-dose study in lean rats, the rats dosed with iBio’s selective amylin receptor agonist had reduced food intake over 24 hours compared with vehicle.

​

iBio plans to advance selective amylin receptor agonists into further preclinical studies in diet-induced obesity models.

​

Presentation Details:

​

ObesityWeek 2026

Title: Deep, Durable Activin E Suppression by Antibody Blockade Drives Fat-Selective Effects in Obese Non-Human Primates

Format: Poster

Date and time: Sunday, November 15, 2026, 2:30–3:30 p.m. ET

Presenter: Cory Schwartz

Location: Gaylord National Resort & Convention Center, National Harbor, Maryland

​

​


PEGS Europe 2026

Title: Beyond Peptides: Engineering GPCR Agonists for Next-Generation Cardiometabolic Therapeutics

Format: Oral presentation

Date and time: Thursday, November 19, 2026, at 11:15 a.m. WET

Presenter: Cody Moore

Location: Lisbon Congress Center, Lisbon, Portugal

​

Amylin-Based Therapeutics Summit

Title: Decoding Amylin Receptor Specificity to Engineer a More Precise, Long-Acting Therapeutic

Format: Presentation

Presenter: Cody Moore

Date and time: Wednesday, December 2, 2026, at 1:30 p.m. ET

Location: Wyndham Boston Beacon Hill

​

Title: Navigating the Efficacy–Tolerability Trade-off: Linking Half-Life, Dosing and Clinical Outcomes to Define Amylin’s Competitive Advantage

Format: Workshop

Leader: Cory Schwartz

Date and time: Tuesday, December 1, 2026, at 1:00 p.m. ET

Location: Wyndham Boston Beacon Hill

​

About iBio, Inc.

iBio (Nasdaq: IBIO) is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

​

For more information, visit www.ibioinc.com or follow us on LinkedIn.

​

Forward-Looking Statements

​

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements include, among others, statements regarding the potential of iBio’s antibody discovery platform to generate highly specific candidates against distinct targets; IBIO-610 potentially being a first-in-class Activin E antibody candidate; IBIO-610’s potential to offer a differentiated approach to long-term weight management; durable Activin E suppression, reductions in fat mass while generally maintaining lean mass, and the newly observed reduction in body weight providing a more comprehensive perspective of how the approach may improve the quality of weight loss; the amylin program’s approach having the potential to improve the balance of efficacy and tolerability; iBio evaluating the selective approach in further studies; having the opportunity to build a complementary portfolio of medicines with the potential to extend the cardiometabolic benefits of weight loss beyond current therapies; the findings further supporting IBIO-610’s potential to promote fat-selective effects while maintaining lean mass; the development of a potential long-acting amylin therapeutic iBio plans to advance selective amylin receptor agonists into further preclinical studies in diet-induced obesity models. These statements reflect iBio’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks associated with the possibility that preclinical findings will not be replicated in humans, iBIO’s ability to successfully develop products, including products for long-term weight management; durable Activin E suppression, reductions in fat mass while generally maintaining lean mass and iBio’s ability to obtain regulatory


approval or any of its products, and the other risks described in iBio’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended June 30, 2026, and subsequent filings.

Forward-looking statements speak only as of the date of this release. iBio undertakes no obligation to update them except as required by law.

​

Investor Contact
Matt Beck
astr partners
matthew.beck@astrpartners.com
(917) 415-1750

​

Media Contact
Jason Braco, Ph.D.
Valence Communications
jason@valencecomms.com


Filing Exhibits & Attachments

5 documents

Keep reading